Search Patents
  • TREATMENT FOR CORONAVIRUS INFECTION AND ASSOCIATED CYTOKINE TOXICITY
    Publication number: 20230120864
    Abstract: The present invention relates to novel methods comprising the administration of pentosan polysulfate for treating or preventing coronavirus infection and cytokine-associated toxicity, including cytokine toxicity resulting from aberrant activation of the immune system in coronavirus disease or infection, such as those from SARS-CoV-2.
    Type: Application
    Filed: March 12, 2021
    Publication date: April 20, 2023
    Inventor: Sydney David Cullis-Hill
  • ACTIVE AGENTS AGAINST CORONAVIRUS INFECTIONS AND DISEASES CAUSED THEREBY
    Publication number: 20230084839
    Abstract: The present invention relates to a novel agent for the prophylactic and therapeutic treatment of a coronavirus infection and/or a disease caused by said infection, a pharmaceutical composition containing said agent, and a method for the prophylactic and/or therapeutic treatment of a coronavirus infection and/or a disease caused by said infection.
    Type: Application
    Filed: October 14, 2022
    Publication date: March 16, 2023
    Inventors: Michael Schindler, Natalia Ruetalo Buschinger, Ramona Businger
  • PHYSICAL METHODS FOR LIVING TISSUE INACTIVATION AND DETECTION, AND PHYSICAL METHODS IN USE FOR THE DETECTION AND INACTIVATION OF LIVING BODIES (LIKE EBOLA AND 2019 CORONAVIRUS) IN LIVING SYSTEMS AND NON-LIVING SYSTEMS THEREOF
    Publication number: 20210378540
    Abstract: A system for detecting presence of coronavirus in a subject, the system including a first pad for placing a first hand, the pad including a contact to measure conductance of the subject's body, a conductance meter connected to the contact, a second pad for placing a second hand, a source of electromagnetic radiation for irradiating the second pad. A system for detecting presence of coronavirus in a subject, the system including a chip with a plurality of wires disposed on or in the chip, a conductance meter arranged to measure conductance between the wires, and biological material associated with the coronavirus disposed on or in the chip. Related apparatus and methods are also described.
    Type: Application
    Filed: August 18, 2021
    Publication date: December 9, 2021
    Inventor: Dorit ARAD
  • SHARK-DERIVED BINDING MOLECULES FOR SARS-COV-2 CORONAVIRUS AND USES THEREOF
    Publication number: 20230331823
    Abstract: Disclosed herein are shark-derived antibodies and binding molecules with high binding affinity for SARS-CoV-2 coronavirus and the use thereof. Some of the shark-derived antibodies and binding molecules also demonstrate cross-reactivity with and neutralization of other related sarbecoviruses. The complementarity determining region (CDR) sequences and binding characteristics for these antibodies and binding molecules are provided. Also disclosed are the use of these antibodies and binding molecules to detect SARS-CoV-2 coronavirus or other related sarbecoviruses or to prevent or treat SARS-CoV-2 coronavirus or other related sarbecovirus infections.
    Type: Application
    Filed: September 15, 2021
    Publication date: October 19, 2023
    Inventors: Michael Gordon JOYCE, Kayvon MODJARRAD, Helen DOOLEY, Agnes HAJDUCZKI, Wei-Hung CHEN
  • DETECTION REAGENT FOR SCREENING BLOCKING AGENT OF CORONAVIRUS INFECTIONS, AND DETECTION METHOD
    Publication number: 20230174592
    Abstract: Disclosed are a fusion protein probe and a cell model for screening a blocking agent of coronavirus infections, a screening system comprising same, and a method of using the screening system for screening a blocking agent of coronavirus infections. The screening system and method do not involve live viruses, are simple and convenient to operate, have a high accuracy, are suitable for high throughput screening, and are of great significance for the development of coronavirus neutralizing antibodies, preventive vaccines, and small molecule drugs.
    Type: Application
    Filed: April 30, 2021
    Publication date: June 8, 2023
    Applicants: YANG SHENG TANG COMPANY, LTD., XIAMEN UNIVERSITY
    Inventors: Yali ZHANG, Shaojuan WANG, Yangtao WU, Wangheng HOU, Jianghui YE, Juan WANG, Tianying ZHANG, Tong CHENG, Quan YUAN, Ningshao XIA
  • PHYSICAL METHODS FOR LIVING TISSUE INACTIVATION AND DETECTION, AND PHYSICAL METHODS IN USE FOR THE DETECTION AND INACTIVATION OF LIVING BODIES (LIKE EBOLA AND 2019 CORONAVIRUS) IN LIVING SYSTEMS AND NON-LIVING SYSTEMS THEREOF
    Publication number: 20230172478
    Abstract: A system for detecting presence of coronavirus in a subject, the system including a first pad for placing a first hand, the pad including a contact to measure conductance of the subject's body, a conductance meter connected to the contact, a second pad for placing a second hand, a source of electromagnetic radiation for irradiating the second pad. A system for detecting presence of coronavirus in a subject, the system including a chip with a plurality of wires disposed on or in the chip, a conductance meter arranged to measure conductance between the wires, and biological material associated with the coronavirus disposed on or in the chip. Related apparatus and methods are also described.
    Type: Application
    Filed: January 30, 2023
    Publication date: June 8, 2023
    Inventor: Dorit ARAD
  • CORONAVIRUS IMMUNOGENIC COMPOSITIONS AND USES THEREOF
    Publication number: 20220072121
    Abstract: CORONAVIRUS IMMUNOGENIC COMPOSITIONS AND USES THEREOF Provided in the present disclosure are immunogenic compounds, pharmaceutical formulations thereof and their use for inducing a protective immune response against 2019 novel coronavirus (SARS-CoV-2) infection and variants in a mammal.
    Type: Application
    Filed: June 9, 2021
    Publication date: March 10, 2022
    Applicant: Altimmune, Inc
    Inventors: Bertrand Victor Gilbert Georges, M. Scot Roberts
  • ANTIVIRAL COMPOSITION AGAINST CORONAVIRUS
    Publication number: 20230357365
    Abstract: An antiviral composition for coronavirus includes an antibody or a functional fragment thereof, which includes a heavy chain CDR1 (VH CDR1) represented by SEQ ID NO: 1, VH CDR2 represented by SEQ ID NO: 2, VH CDR3 represented by SEQ ID NO: 3, a light chain CDR1 (VL CDR1) represented by SEQ ID NO: 4, VL CDR2 represented by SEQ ID NO: 5, and VL CDR3 represented by SEQ ID NO: 6, so as to exhibit excellent antiviral effects to coronavirus, while achieving effects of preventing, treating or improving diseases derived from coronavirus.
    Type: Application
    Filed: August 9, 2021
    Publication date: November 9, 2023
    Inventors: Tai Hyun KIM, Kwang Ji OH, Won Keun KIM
  • Coronavirus Spike Glycoprotein With Improved Expression and Stability
    Publication number: 20230398204
    Abstract: The present invention includes a mutant coronavirus spike protein, methods of making and using, vaccines, vectors and nucleic acids, comprising at least one of the following modifications: a short flexible peptide linker or a rigid peptide linker in place of the furin cleavage site loop to genetically link an 51 and S2 subunit; at least one additional disulfide bond; or 1, 2, 3, 4, or 5 proline mutations for greater trimeric stability, wherein the resulting mutant coronavirus spike protein has at least one of: a higher stability or a higher level of expression when compared to a non-modified coronavirus spike protein. In one example, the coronavirus is SARS, MERS, 229E (alpha), NL63 (alpha), OC43 (beta), HKU1 (beta), SARS-CoV-2, or an emerging variant thereof. Current SARS-CoV-2 variants include, e.g., B.1.1.7, B.1.1.7 with E484K, B.1.135, B.1.351, P.1, B.1.427, D614G, B.1.1351, or B.1.429, Lambda (i.e., C.37), Mu (i.e. B.1.621), and others.
    Type: Application
    Filed: October 21, 2020
    Publication date: December 14, 2023
    Inventors: Erica Ollman Saphire, Eduardo Olmedillas, Colin Mann
  • Anti-coronavirus drug
    Patent number: 7495011
    Abstract: The present invention provides an anti-coronavirus agent including as an active ingredient as exemplified by nelfinavir and salts thereof, an anti-SARS agent including the anti-coronavirus agent, and a method of treating SARS using the anti-SARS agent.
    Type: Grant
    Filed: July 14, 2004
    Date of Patent: February 24, 2009
    Assignee: aRigen Pharmaceuticals, Inc.
    Inventors: Nobutaka Fujii, Naoki Yamamoto
  • FULLY HUMAN BROAD-SPECTRUM NEUTRALIZING ANTIBODY 76E1 AGAINST CORONAVIRUS, AND USE THEREOF
    Publication number: 20240067706
    Abstract: Disclosed are a fully human broad-spectrum neutralizing antibody against coronavirus, and the use thereof. Specifically disclosed are a fully human monoclonal antibody against an S2 region of coronavirus S protein, a nucleic acid sequence encoding the antibody, and a preparation method therefor. The antibody can effectively bind to and neutralize a variety of coronaviruses in a broad spectrum manner, and can be used for preventing and treating diseases related to coronavirus infection, such as SARS-CoV-2. Further disclosed is the potential use thereof in vaccine design.
    Type: Application
    Filed: January 5, 2022
    Publication date: February 29, 2024
    Applicant: CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE, CHINESE ACADEMY OF SCIENCES
    Inventors: Bing Sun, Xiaoyu Sun, Chunyan Yi, Zhiyang Ling, Yaguang Zhang
  • Treatment for coronavirus infection and associated cytokine toxicity
    Patent number: 11938146
    Abstract: The present invention relates to novel methods for treating or preventing coronavirus infection and cytokine-associated toxicity, including cytokine toxicity resulting from aberrant activation of the immune system in coronavirus disease or infection, such as those from SARS-CoV-2.
    Type: Grant
    Filed: November 30, 2022
    Date of Patent: March 26, 2024
    Inventor: Sydney David Cullis-Hill
  • METHOD AND PLATFORM FOR ENHANCING DETECTION ACTIVITY OF INTERACTION BETWEEN SPIKE PROTEIN RECEPTOR BINDING DOMAIN OF CORONAVIRUS FROM SPECIMEN AND HUMAN ANGIOTENSIN-CONVERTING ENZYME II
    Publication number: 20220412959
    Abstract: The present disclosure provides a method and a platform for enhancing detection activity of an interaction between a spike protein receptor binding domain of coronavirus from a specimen and a human angiotensin-converting enzyme II. The method and the platform of the present disclosure use a cleavable luciferase as a report test for the combination of the spike protein receptor binding domain of coronavirus (such as novel coronavirus) and angiotensin-converting enzyme II. Screening is carried out at the cellular level. The strength of the drug's influence on the interaction between the two molecules can be judged by the strength of the luminescence signal. The detection time can be completed within 20 minutes.
    Type: Application
    Filed: October 19, 2021
    Publication date: December 29, 2022
    Inventors: Hui-Ching Wang, Tian-Neng Li
  • METHOD FOR THE PROPHYLAXIS OR TREATMENT OF CORONAVIRUS INFECTION USING AN IMMUNOMODULATOR AND VACCINE COMPOSITIONS COMPRISING THE SAME
    Publication number: 20240189419
    Abstract: The present disclosure provides a method for the treatment or prophylaxis of coronavirus infection, comprising administering a therapeutically effective amount of an immunomodulator to a subject in need thereof or at risk of coronavirus infection. A vaccine composition comprising a pharmaceutically effective amount of an immunomodulator is also provided.
    Type: Application
    Filed: February 21, 2024
    Publication date: June 13, 2024
    Inventors: YU-SHEN HSU, SSU-WEI KANG, MING-I CHANG
  • Coronavirus
    Publication number: 20170216427
    Abstract: The present invention provides a live, attenuated coronavirus comprising a variant replicase gene encoding polyproteins comprising a mutation in one or more of non-structural protein(s) (nsp)-10, nsp-14, nsp-15 or nsp-16. The coronavirus may be used as a vaccine for treating and/or preventing a disease, such as infectious bronchitis, in a subject.
    Type: Application
    Filed: July 23, 2015
    Publication date: August 3, 2017
    Inventors: Erica Bickerton, Sarah Keep, Paul Britton
  • Coronavirus
    Patent number: 10130701
    Abstract: The present invention provides a live, attenuated coronavirus comprising a variant replicase gene encoding polyproteins comprising a mutation in one or more of non-structural protein(s) (nsp)-10, nsp-14, nsp-15 or nsp-16. The coronavirus may be used as a vaccine for treating and/or preventing a disease, such as infectious bronchitis, in a subject.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: November 20, 2018
    Assignee: THE PIRBRIGHT INSTITUTE
    Inventors: Erica Bickerton, Sarah Keep, Paul Britton
  • Modified S1 subunit of the coronavirus spike protein
    Patent number: 11512115
    Abstract: The present invention relates i.a. to a recombinant avian coronavirus spike protein or fragment thereof comprising a mutation at amino acid position 267 to Cysteine. Further, the present invention relates to an immunogenic composition comprising an avian coronavirus with such spike protein.
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: November 29, 2022
    Inventors: Annika Kraemer-Kuehl, Thomas Min Stephan, Hans-Christian Philipp
  • Multivalent bovine coronavirus vaccine and method of treating bovine coronavirus infection
    Patent number: 5916570
    Abstract: New purified and isolated bovine coronavirus (BCV) types (II and III) are described which can be used to create new modified live vaccines for administration to cattle in order to confer immunity against virulent wild-type bovine coronavirus infection. Preferably, a multivalent modified live vaccine is provided for oral-nasal administration which includes the known Type I virus and the new Types II and III virus. Hygromycin B has also demonstrated to be effective for suppressing BCV replication and thus can be administered to cattle as a treatment for the chronic disease and to suppress shedding of BCV in cattle feces.
    Type: Grant
    Filed: February 4, 1997
    Date of Patent: June 29, 1999
    Assignee: Kansas State University Research Foundation
    Inventor: Sanjay Kapil
  • MONOCLONAL ANTIBODY FOR CORONAVIRUS SPIKE PROTEIN, AND USE THEREOF
    Publication number: 20230391854
    Abstract: Provided are an antibody or an antigen-binding fragment for a coronavirus S protein, a nucleic acid encoding the antibody or the antigen-binding fragment, a host cell comprising the nucleic acid, and a method for preparing the antibody or the antigen-binding fragment. Also provided is a use of the antibody or the antigen-binding fragment in prevention, treatment, and/or diagnosis of coronavirus.
    Type: Application
    Filed: September 9, 2021
    Publication date: December 7, 2023
    Inventors: Jia ZOU, Li LI, Shuaixiang ZHOU, Jianxing HE
  • Methods of assessing risk of developing a severe response to coronavirus infection
    Patent number: 11257569
    Abstract: The present disclosure relates to methods and systems for assessing the risk of a human subject developing a severe response to a Coronavirus infection, such as a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus infection.
    Type: Grant
    Filed: July 6, 2021
    Date of Patent: February 22, 2022
    Assignee: GENETIC TECHNOLOGIES LIMITED
    Inventors: Gillian Sue Dite, Nicholas Mark Murphy, Richard Allman
Narrow Results

Filter by US Classification